Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 4 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Cue Biopharma Inc. maintains a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The company currently faces 5 pending office actions that are being processed by 5 distinct examiners. Because the number of 5 distinct examiners is equal to the number of 5 pending office actions, each examiner is currently responsible for a single matter for the portfolio.
These prosecution efforts are spread across 4 distinct art units. CLAUDIA EDILMA ESPINOSA is the busiest examiner for the company, with 1 pending office action under review. This workload for CLAUDIA EDILMA ESPINOSA represents 1 of the 5 pending office actions currently active for Cue Biopharma Inc. The use of 4 distinct art units suggests the portfolio covers multiple technical sub-sectors within its technology area.
The presence of 5 pending office actions across 4 distinct art units indicates that the company is engaging with several different examination groups. This distribution can prevent a single examiner from impacting the entire portfolio. With CLAUDIA EDILMA ESPINOSA and the other examiners each managing 1 pending office action, the workload is distributed across the 5 distinct examiners. Practitioners should note that the coverage of 4 distinct art units may require different technical approaches for each unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 3 (50%) |
| Multi-statute (no §101) | 3 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ESPINOSA, CLAUDIA EDILMA | 1 | 50.9% | +57.7% |
| ZOU, NIANXIANG | 1 | 64.1% | +24.8% |
| STOICA, ELLY GERALD | 1 | 66.9% | +22.5% |
| AEDER, SEAN E | 1 | 57.0% | +19.9% |
| QIAN, CELINE X | 1 | 47.6% | +16.9% |
| BLUMEL, BENJAMIN P | 1 | 70.8% | +30.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18005813 | T-Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use Thereof | QIAN, CELINE X | 18d overdue |
| 18903947 | T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | ESPINOSA, CLAUDIA EDILMA | — |
| 17822584 | T CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | BLUMEL, BENJAMIN P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18005813 | T-Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use Thereof | QIAN, CELINE X | 18d overdue |
| 18903947 | T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | ESPINOSA, CLAUDIA EDILMA | — |
| 18653683 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | ZOU, NIANXIANG | — |
| 18287747 | Antigen Presenting Polypeptide Complexes Bearing TGF-Beta and Methods of Use Thereof | STOICA, ELLY GERALD | — |
| 18287739 | Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use Thereof | AEDER, SEAN E | — |
| 17822584 | T CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | BLUMEL, BENJAMIN P | — |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| 1671 | 2 |
| 1647 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18903947 | T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | ESPINOSA, CLAUDIA EDILMA | 1654 | §103§112Other | Non-Final OA | — | Pending | Oct 01, 2024 |
| 18653683 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | ZOU, NIANXIANG | 1671 | §103§112DP | Non-Final OA | — | Pending | May 02, 2024 |
| 18287747 | Antigen Presenting Polypeptide Complexes Bearing TGF-Beta and Methods of Use Thereof | STOICA, ELLY GERALD | 1647 | §112DP | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18287739 | Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use Thereof | AEDER, SEAN E | 1654 | §112DP | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18005813 | T-Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use Thereof | QIAN, CELINE X | 1637 | §102§103§112Other | Final Rejection | 18d overdue | Pending | Jan 17, 2023 |
| 17822584 | T CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | BLUMEL, BENJAMIN P | 1671 | §103§112 | Non-Final OA | — | Pending | Aug 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial